Galapagos buys structure-based discovery outfit; Pfizer reportedly considering Strides Arcolabs bid;

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Belgium's Galapagos NV is adding to its discovery engine with the acquisition of U.K.-based Cangenix, which does structure-based discovery work. Release

> Quoting insiders, Bloomberg reports that Pfizer ($PFE) is among the suitors considering a possible offer for Strides Arcolabs' injectable medicines unit. Story

> Denver-based InDevR has spun off ViroCyt, securing funding from a group of investors led by High Country Venture. Release

Pharma News

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of AstraZeneca's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> Tired of empty shelves, CVS stops stocking Tylenol in some stores. Story

> Forest's Lexapro plague lingers with 41% hit to Q3 sales. News

> New AZ chief sends top execs packing in management shuffle. Report

Medical Device News

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Saliva gland could be secret to a Parkinson's disease Dx. Story

> St. Jude hit with FDA warning letter over Durata manufacturing. News

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

> Stem cells show early promise in ALS. More

And Finally… A Massachusetts General Hospital study concludes that generic drugs are cheaper but less effective than their newer rivals. And simpler dosing schedules make compliance more likely, investigators add. Story